Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials-Reference-Cited by-同舟云学术

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials

Published:2014-08-10 Issue:19 Volume:5 Page:8937-8946
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Said Rabih¹²,Ye Yang¹,Falchook Gerald Steven¹,Janku Filip¹,Naing Aung¹,Zinner Ralph¹,Blumenschein George R.³,Fu Siqing¹,Hong David S.¹,Piha-Paul Sarina Anne¹,Wheler Jennifer J.¹,Kurzrock Razelle⁴,Palmer Gary A.⁵,Aldape Kenneth⁶,Hess Kenneth R.⁷,Tsimberidou Apostolia Maria¹

Affiliation:

1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

2. Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX

3. Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

4. Department of Internal Medicine, Moores Cancer Center - University of California San Diego, LaJolla, CA

5. Foundation Medicine, Inc., Cambridge, MA

6. Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

7. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer;ESMO Gastrointestinal Oncology;2024-09

2. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum;Journal of Clinical Oncology;2020-11-10

3. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer;Oncotarget;2017-04-05

4. MultiplexKRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction;Annals of Oncology;2017-03

5. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers;Clinical Cancer Research;2017-01-17